Q2 2024 EPS Estimates for Revvity, Inc. (NYSE:RVTY) Decreased by Analyst

Revvity, Inc. (NYSE:RVTY) – Research analysts at Zacks Research lowered their Q2 2024 earnings per share estimates for shares of Revvity in a research note issued to investors on Monday, May 20th. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will post earnings per share of $1.15 for the quarter, down from their previous estimate of $1.16. The consensus estimate for Revvity’s current full-year earnings is $4.66 per share. Zacks Research also issued estimates for Revvity’s Q3 2024 earnings at $1.16 EPS, Q2 2025 earnings at $1.29 EPS, Q4 2025 earnings at $1.44 EPS and FY2025 earnings at $5.17 EPS.

Revvity (NYSE:RVTY) last announced its earnings results on Monday, April 29th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.04. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The company had revenue of $649.90 million during the quarter, compared to analysts’ expectations of $646.83 million. During the same quarter in the previous year, the business posted $1.01 earnings per share. Revvity’s quarterly revenue was down 3.7% on a year-over-year basis.

A number of other equities analysts have also commented on RVTY. Robert W. Baird raised their price objective on Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 30th. Stifel Nicolaus boosted their price target on Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. Raymond James increased their price objective on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. KeyCorp boosted their target price on shares of Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Finally, TD Cowen increased their price target on shares of Revvity from $123.00 to $130.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Revvity has an average rating of “Moderate Buy” and an average target price of $118.17.

Revvity Stock Down 0.7 %

Shares of RVTY opened at $111.89 on Wednesday. The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $13.81 billion, a PE ratio of 92.47, a P/E/G ratio of 2.94 and a beta of 1.09. The firm’s 50 day moving average is $104.57 and its 200-day moving average is $102.50. Revvity has a 12 month low of $79.50 and a 12 month high of $131.96.

Revvity Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.25%. The ex-dividend date of this dividend is Friday, July 19th. Revvity’s dividend payout ratio is currently 23.14%.

Hedge Funds Weigh In On Revvity

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Parkside Financial Bank & Trust acquired a new stake in Revvity during the fourth quarter worth approximately $25,000. Gladius Capital Management LP lifted its position in shares of Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after acquiring an additional 106 shares during the period. CENTRAL TRUST Co bought a new position in Revvity during the fourth quarter worth $27,000. Benjamin F. Edwards & Company Inc. acquired a new stake in Revvity in the fourth quarter worth $27,000. Finally, ORG Partners LLC bought a new stake in Revvity in the fourth quarter valued at $32,000. 86.65% of the stock is owned by institutional investors and hedge funds.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.